These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26865694)

  • 1. Identification of Low-Level Vancomycin Resistance in Staphylococcus aureus in the Era of Informatics.
    Ford BA
    J Clin Microbiol; 2016 Apr; 54(4):836-9. PubMed ID: 26865694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Detection of Vancomycin-Intermediate Staphylococcus aureus by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.
    Mather CA; Werth BJ; Sivagnanam S; SenGupta DJ; Butler-Wu SM
    J Clin Microbiol; 2016 Apr; 54(4):883-90. PubMed ID: 26763961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Srisrattakarn A; Chaiyapoke C; Booncharoen S; Wongthong S; Chanawong A; Tippayawat P; Tavichakorntrakool R; Lulitanond A
    Turk J Med Sci; 2021 Aug; 51(4):2150-2158. PubMed ID: 33705643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG; Gao W; Ward PB; Howden BP
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and easy detection of low-level resistance to vancomycin in methicillin-resistant Staphylococcus aureus by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
    Asakura K; Azechi T; Sasano H; Matsui H; Hanaki H; Miyazaki M; Takata T; Sekine M; Takaku T; Ochiai T; Komatsu N; Shibayama K; Katayama Y; Yahara K
    PLoS One; 2018; 13(3):e0194212. PubMed ID: 29522576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.
    Howden BP; Davies JK; Johnson PD; Stinear TP; Grayson ML
    Clin Microbiol Rev; 2010 Jan; 23(1):99-139. PubMed ID: 20065327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
    Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
    J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.
    Matsuo M; Cui L; Kim J; Hiramatsu K
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5843-53. PubMed ID: 24018261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
    Gomes DM; Ward KE; LaPlante KL
    Pharmacotherapy; 2015 Apr; 35(4):424-32. PubMed ID: 25884530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore.
    Fong RK; Low J; Koh TH; Kurup A
    Eur J Clin Microbiol Infect Dis; 2009 Aug; 28(8):983-7. PubMed ID: 19387707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.
    Khatib R; Riederer K; Sharma M; Shemes S; Iyer SP; Szpunar S
    J Clin Microbiol; 2015 Nov; 53(11):3543-6. PubMed ID: 26311860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key considerations in the treatment of complicated staphylococcal infections.
    Jones RN
    Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).
    Howden BP
    Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hVISA/VISA: diagnostic and therapeutic problems.
    Szabó J
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):1-3. PubMed ID: 19622051
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital.
    da Costa TM; Morgado PG; Cavalcante FS; Damasco AP; Nouér SA; Dos Santos KR
    PLoS One; 2016; 11(8):e0160506. PubMed ID: 27575698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced vancomycin susceptibility and increased macrophage survival in Staphylococcus aureus strains sequentially isolated from a bacteraemic patient during a short course of antibiotic therapy.
    Basco MDS; Kothari A; McKinzie PB; Revollo JR; Agnihothram S; Azevedo MP; Saccente M; Hart ME
    J Med Microbiol; 2019 Jun; 68(6):848-859. PubMed ID: 31136294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.
    Hu J; Ma XX; Tian Y; Pang L; Cui LZ; Shang H
    PLoS One; 2013; 8(9):e73300. PubMed ID: 24069184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.